- Home
- CGEN vs ACRV Comparison
CGEN vs ACRV Comparison
Compare CGEN & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- ACRV
- Stock Information
- Founded
- CGEN 1993
- ACRV 2018
- Country
- CGEN Israel
- ACRV United States
- Employees
- CGEN N/A
- ACRV N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- CGEN Health Care
- ACRV Health Care
- Exchange
- CGEN Nasdaq
- ACRV Nasdaq
- Market Cap
- CGEN 149.6M
- ACRV 172.5M
- IPO Year
- CGEN 2000
- ACRV 2022
- Fundamental
- Price
- CGEN $1.56
- ACRV $5.49
- Analyst Decision
- CGEN Strong Buy
- ACRV Strong Buy
- Analyst Count
- CGEN 1
- ACRV 6
- Target Price
- CGEN $4.00
- ACRV $22.40
- AVG Volume (30 Days)
- CGEN 299.7K
- ACRV 25.8K
- Earning Date
- CGEN 03-04-2025
- ACRV 05-13-2025
- Dividend Yield
- CGEN N/A
- ACRV N/A
- EPS Growth
- CGEN N/A
- ACRV N/A
- EPS
- CGEN N/A
- ACRV N/A
- Revenue
- CGEN $27,864,000.00
- ACRV N/A
- Revenue This Year
- CGEN $22.94
- ACRV N/A
- Revenue Next Year
- CGEN $15.88
- ACRV N/A
- P/E Ratio
- CGEN N/A
- ACRV N/A
- Revenue Growth
- CGEN N/A
- ACRV N/A
- 52 Week Low
- CGEN $1.35
- ACRV $4.69
- 52 Week High
- CGEN $2.66
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- CGEN 38.91
- ACRV 52.82
- Support Level
- CGEN $1.54
- ACRV $5.00
- Resistance Level
- CGEN $1.64
- ACRV $5.65
- Average True Range (ATR)
- CGEN 0.08
- ACRV 0.29
- MACD
- CGEN 0.01
- ACRV 0.04
- Stochastic Oscillator
- CGEN 26.92
- ACRV 89.71
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.